Core Insights - Senseonics Holdings, Inc. reported preliminary unaudited revenue of approximately $14.2 million for Q4 2025, marking a 71% increase year-over-year [1][5] - The company introduced revenue guidance for 2026, estimating global net revenue to be between $58 million and $62 million, which represents a growth of 65% to 76% compared to 2025 [4] - The company plans to report its full-year 2025 financial results on March 2, 2026 [1][6] Financial Performance - The total revenue for the full year 2025 is expected to be approximately $35.2 million, reflecting a 57% increase year-over-year [5][6] - The unaudited balance of cash, cash equivalents, and restricted cash as of December 31, 2025, is projected to be around $94.3 million [5] Business Developments - The company achieved a 103% growth in new patients in the U.S. during Q4 2025 compared to the same period in 2024, driven by direct-to-consumer marketing efforts [6] - Senseonics secured FDA Investigational Device Exemption (IDE) approval to commence a pivotal trial for the Gemini sensor and has enrolled the first patients [6] - The transition of commercialization and distribution rights for Eversense 365 from Ascensia is expected to enhance revenue and gross margins starting January 1, 2026 [3][4] Future Outlook - The company anticipates a boost in revenue from the expected CE mark approval in Europe for Eversense 365 and the launch of the twiist system with full Eversense compatibility [3] - The completion of the Gemini trial is expected in the second half of 2026, contributing to future growth [3]